<p><strong>全球首个全合成重组版本的 PRP</strong></p>
<p>墨尔本，2026 年 1 月 20 日（全球新闻稿）—— Propanc Biopharma, Inc.（纳斯达克：PPCB）（“Propanc” 或 “公司”）是一家专注于开发慢性疾病新疗法的生物制药公司，包括复发性和转移性癌症，今天宣布已向澳大利亚知识产权局提交了一项新的临时专利申请，涉及生产胰蛋白酶原和胰凝乳蛋白酶原的方法。该专利申请描述了一种优化的表达系统，以生产全球首个全合成重组版本的 PRP，这是一种用于治疗和预防固体肿瘤转移性癌症的长期疗法。根据 Emergen Research 的报告，全球转移性癌症市场预计到 2027 年将达到 1110 亿美元。</p>
<p>一种全合成的胰蛋白酶原和胰凝乳蛋白酶原，称为 Rec-PRP，可能对全球医疗系统带来额外的好处，进一步利用一种新的癌症治疗方法。例如，这两种前酶是通过体内（活生物体）表达系统合成的，例如酵母细胞，以生产可以在没有冷藏的情况下长时间保持的蛋白质。这对于延长保质期以及全球分发非常有用，特别是在没有冷藏设施的温暖气候和发展中地区。此外，该项目可以生产大量用于商业用途的胰蛋白酶原和胰凝乳蛋白酶原，且批次之间的变异最小，并且不需要从动物中获取。因此，管理层认为，全合成重组版本的 PRP 在监管方面将具有巨大的影响，同时也为全球分发带来实际的商业利益。</p>
<p>“这项临时专利申请是过去两个月内提交的第三项，将显著增强我们的知识产权组合，因为我们进入各国的国家阶段，针对这些专利申请，” Propanc 首席执行官詹姆斯·纳撒尼尔斯（Mr. James Nathanielsz）表示。“我们继续执行我们的战略计划，建立一个可能成为全球首个针对固体肿瘤转移性癌症的治疗方法的平台技术，但没有与标准治疗相关的严重或严重副作用。此外，我们正在扩大对其他治疗适应症的研究，这些适应症存在显著的未满足医疗需求。我们正在为我们的公司和股东建立一个强大而稳定的未来。”</p>
<p><strong>关于 Propanc Biopharma, Inc.</strong></p>
<p>Propanc Biopharma, Inc.（纳斯达克：PPCB）正在开发一种新方法，通过靶向和消灭癌症干细胞来防止癌症复发和转移，方法是通过前酶激活。公司的主要产品候选者 PRP 旨在解决癌症增殖和扩散的根本驱动因素。</p>
<p><strong>更多信息：</strong> www.propanc.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿中所有非历史性的声明均为前瞻性声明，包括但不限于与公司对其市场地位和市场机会的预期、产品开发、制造和销售的预期和计划，以及与其合作伙伴和投资者的关系相关的声明，这些声明是基于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的安全港条款。 这些声明不是历史事实，而是基于公司当前的预期、估计和对其业务、运营及其他类似或相关因素的预测。诸如 “可能”、“将”、“可以”、“会”、“应该”、“预期”、“预测”、“潜在”、“继续”、“期望”、“打算”、“计划”、“项目”、“相信”、“估计” 等词语用于识别这些前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性和假设，这些因素难以或不可能预测，并且在某些情况下超出公司的控制范围。前瞻性声明并不是未来行动或表现的保证。实际结果可能因多种因素而与前瞻性声明中的结果大相径庭，包括但不限于与市场条件相关的风险和不确定性，以及在与拟议发行相关的招股说明书中描述的 “风险因素” 以及公司向美国证券交易委员会提交的文件中描述的风险。公司没有义务修订或更新本声明中的信息，以反映未来的事件或情况，即使新信息变得可用。</p>
<p><strong>公司：</strong></p>
<p>Propanc Biopharma, Inc.</p>
<p>詹姆斯·纳撒尼尔斯</p>
<p>+61-3-9882-0780</p>
<p>info@propanc.com</p>
<p><strong>投资者联系：</strong></p>
<p>irteam@propanc.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9ETTBPU00zTXpZNU16VTBJekl5T1RFeE1UST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9ETTBPU00zTXpZNU16VTBJekl5T1RFeE1UST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGZhOWI0N2YtYjAwZS00NTRlLWI3NDUtOTYyNTZhM2ZiNmFlLTEzMDI2NjItMjAyNi0wMS0yMC1lbg==/tiny/Propanc-Biopharma-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGZhOWI0N2YtYjAwZS00NTRlLWI3NDUtOTYyNTZhM2ZiNmFlLTEzMDI2NjItMjAyNi0wMS0yMC1lbg==/tiny/Propanc-Biopharma-Inc-.png"/></p>

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

PPCB

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

<p>Propanc Biopharma, Inc. 已向澳大利亚知识产权局提交了一项新的临时专利申请，旨在开发生产胰蛋白酶原和胰凝乳蛋白酶原的方法。该申请旨在创造一种完全合成的重组 PRP 版本，可能会增强对转移性癌症的治疗。公司相信，这一创新将改善产品的全球分销和保质期，特别是在缺乏制冷设施的地区。首席执行官 James Nathanielsz 强调了这一专利在加强他们的知识产权组合和推进癌症治疗战略计划中的重要性</p>

<p><strong>A World-First, Fully Synthetic Recombinant Version of PRP</strong></p>
<div class="lb-trans"><p><strong>全球首个全合成重组版本的 PRP</strong></p>
</div><p>MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a new provisional patent application has been filed for methods of producing trypinsogen and chymotrypsinogen with IP Australia. The patent application describes an optimized expression system to produce a world-first fully synthetic recombinant version of PRP, a long-term therapy for the treatment and prevention of metastatic cancer from solid tumors. According to Emergen Research, the global metastatic cancer market is projected to be worth $111 Billion by 2027.</p>
<div class="lb-trans"><p>墨尔本，2026 年 1 月 20 日（全球新闻稿）—— Propanc Biopharma, Inc.（纳斯达克：PPCB）（“Propanc” 或 “公司”）是一家专注于开发慢性疾病新疗法的生物制药公司，包括复发性和转移性癌症，今天宣布已向澳大利亚知识产权局提交了一项新的临时专利申请，涉及生产胰蛋白酶原和胰凝乳蛋白酶原的方法。该专利申请描述了一种优化的表达系统，以生产全球首个全合成重组版本的 PRP，这是一种用于治疗和预防固体肿瘤转移性癌症的长期疗法。根据 Emergen Research 的报告，全球转移性癌症市场预计到 2027 年将达到 1110 亿美元。</p>
</div><p>A fully synthetic version of trypsinogen and chymotrypsinogen, called Rec-PRP, could have additional benefits to a global healthcare system that further capitalizes on a new therapeutic approach to treating cancer. For example, both proenzymes are synthesized by an <em>in vivo</em> (living organism) expression system, such as yeast cells, to produce proteins that could be maintained for long periods of time without suffering degradation in the absence of refrigeration. This is useful for a longer self-life as well as global distribution, particularly in warmer climates and developing regions where refrigeration is not available. Further, the program could produce large quantities of trypsinogen and chymotrypsinogen for commercial use that exhibits minimal variation between lots and without sourcing from animals. Therefore, management believes a fully synthetic recombinant version of PRP would have tremendous implications from a regulatory perspective, but also a practical, commercial benefit for global distribution.</p>
<div class="lb-trans"><p>一种全合成的胰蛋白酶原和胰凝乳蛋白酶原，称为 Rec-PRP，可能对全球医疗系统带来额外的好处，进一步利用一种新的癌症治疗方法。例如，这两种前酶是通过体内（活生物体）表达系统合成的，例如酵母细胞，以生产可以在没有冷藏的情况下长时间保持的蛋白质。这对于延长保质期以及全球分发非常有用，特别是在没有冷藏设施的温暖气候和发展中地区。此外，该项目可以生产大量用于商业用途的胰蛋白酶原和胰凝乳蛋白酶原，且批次之间的变异最小，并且不需要从动物中获取。因此，管理层认为，全合成重组版本的 PRP 在监管方面将具有巨大的影响，同时也为全球分发带来实际的商业利益。</p>
</div><p>“This provisional patent application is the third one filed over the past two months and will enhance our IP portfolio significantly as we enter national phase in countries worldwide for each of these patent applications,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We continue to execute our strategic plan building a platform technology that could be a world-first therapeutic approach to metastatic cancer from solid tumors, but without severe or serious side effects associated with standard treatments. Further, we are expanding our research into other therapeutic indications where there is a significant unmet medical need. We are building a strong and stable future for our Company and shareholders over the long term.”</p>
<div class="lb-trans"><p>“这项临时专利申请是过去两个月内提交的第三项，将显著增强我们的知识产权组合，因为我们进入各国的国家阶段，针对这些专利申请，” Propanc 首席执行官詹姆斯·纳撒尼尔斯（Mr. James Nathanielsz）表示。“我们继续执行我们的战略计划，建立一个可能成为全球首个针对固体肿瘤转移性癌症的治疗方法的平台技术，但没有与标准治疗相关的严重或严重副作用。此外，我们正在扩大对其他治疗适应症的研究，这些适应症存在显著的未满足医疗需求。我们正在为我们的公司和股东建立一个强大而稳定的未来。”</p>
</div><p><strong>About Propanc Biopharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Propanc Biopharma, Inc.</strong></p>
</div><p>Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.</p>
<div class="lb-trans"><p>Propanc Biopharma, Inc.（纳斯达克：PPCB）正在开发一种新方法，通过靶向和消灭癌症干细胞来防止癌症复发和转移，方法是通过前酶激活。公司的主要产品候选者 PRP 旨在解决癌症增殖和扩散的根本驱动因素。</p>
</div><p><strong>More information:</strong> www.propanc.com</p>
<div class="lb-trans"><p><strong>更多信息：</strong> www.propanc.com</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.</p>
<div class="lb-trans"><p>本新闻稿中所有非历史性的声明均为前瞻性声明，包括但不限于与公司对其市场地位和市场机会的预期、产品开发、制造和销售的预期和计划，以及与其合作伙伴和投资者的关系相关的声明，这些声明是基于《1933 年证券法》第 27A 条和《1934 年证券交易法》第 21E 条的安全港条款。 这些声明不是历史事实，而是基于公司当前的预期、估计和对其业务、运营及其他类似或相关因素的预测。诸如 “可能”、“将”、“可以”、“会”、“应该”、“预期”、“预测”、“潜在”、“继续”、“期望”、“打算”、“计划”、“项目”、“相信”、“估计” 等词语用于识别这些前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。您不应对前瞻性声明过于依赖，因为它们涉及已知和未知的风险、不确定性和假设，这些因素难以或不可能预测，并且在某些情况下超出公司的控制范围。前瞻性声明并不是未来行动或表现的保证。实际结果可能因多种因素而与前瞻性声明中的结果大相径庭，包括但不限于与市场条件相关的风险和不确定性，以及在与拟议发行相关的招股说明书中描述的 “风险因素” 以及公司向美国证券交易委员会提交的文件中描述的风险。公司没有义务修订或更新本声明中的信息，以反映未来的事件或情况，即使新信息变得可用。</p>
</div><p><strong>Company:</strong></p>
<div class="lb-trans"><p><strong>公司：</strong></p>
</div><p>Propanc Biopharma, Inc.</p>
<div class="lb-trans"><p>Propanc Biopharma, Inc.</p>
</div><p>James Nathanielsz</p>
<div class="lb-trans"><p>詹姆斯·纳撒尼尔斯</p>
</div><p>+61-3-9882-0780</p>
<div class="lb-trans"><p>+61-3-9882-0780</p>
</div><p>info@propanc.com</p>
<div class="lb-trans"><p>info@propanc.com</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>irteam@propanc.com</p>
<div class="lb-trans"><p>irteam@propanc.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU9ETTBPU00zTXpZNU16VTBJekl5T1RFeE1UST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyODM0OSM3MzY5MzU0IzIyOTExMTI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZGZhOWI0N2YtYjAwZS00NTRlLWI3NDUtOTYyNTZhM2ZiNmFlLTEzMDI2NjItMjAyNi0wMS0yMC1lbg==/tiny/Propanc-Biopharma-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZGZhOWI0N2YtYjAwZS00NTRlLWI3NDUtOTYyNTZhM2ZiNmFlLTEzMDI2NjItMjAyNi0wMS0yMC1lbg==/tiny/Propanc-Biopharma-Inc-.png"/></p>

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia | PPCB Stock News

StockTitan

Propanc Biopharma

Propanc Biopharma 向澳大利亚知识产权局提交了关于生产胰蛋白酶原和糜蛋白酶原方法的新临时专利申请 | PPCB 股票新闻